Berkeley, California — Newomics Inc., a biotechnology company specializing in innovative mass spectrometry solutions for molecular detection, today announced a global co-marketing collaboration with Shimadzu Corporation, a leading provider of analytical and measurement technologies for life science research. The companies will work together to advance integrated mass spectrometry solutions for applications in therapeutic drug discovery, clinical research, environmental analysis, and other areas.
Under the co-marketing agreement, Newomics’s mass spectrometry front-end technologies will be combined with Shimadzu’s Q-TOF and Triple Quadrupole LC-MS systems. The resulting UniESI-MS solutions are designed to deliver high sensitivity, robustness, and reproducibility while enabling high-throughput analysis of small sample volumes across proteins, oligonucleotides, small molecules, and other analytes.
“This agreement builds on the close collaboration between our respective teams over the past three years,” said Ash Toyama, Ph.D., Global Product Manager (LCMS) at Shimadzu Corporation. “We look forward to partnering with Newomics to develop robust workflows that leverage Newomics’s mass spec front-end systems on our mass spectrometers. These bioanalytical applications will meet the needs of our diverse customers globally.”
“We are excited to expand our collaboration with Shimadzu Corporation,” said Daojing Wang, Ph.D., Founder and CEO of Newomics. “Together, we have demonstrated excellent sensitivity and reproducibility for GLP-1 and PFAS analyses by combining Newomics’s multinozzle M3 emitters with Shimadzu’s powerful Triple Quadrupole MS systems. Looking ahead, we are excited to explore the integration of our new UniDirect HT-MS platform with Shimadzu’s high-resolution mass spectrometers and next-generation technologies, including the Multi-turn TOF platform showcased at ASMS 2026. These complementary technologies could enable new high-throughput applications in proteomics, metabolomics, biologics analysis, and beyond.”
